All In Biotech

Drug Trial Radar · NCT07332455

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Dose Optimization Study of GSK5471713 in Adult Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

54

Planned (sponsor's estimate)

Start

Feb 10, 2026

Primary completion

Mar 24, 2028

Study completion Mar 26, 2030

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.

Conditions

  • Neoplasms, Prostate

Interventions

  • GSK5471713Drug

    GSK5471713 will be administered at different dose levels based on the dose escalation study design

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicities (DLTs)Time frame: 28 days
  2. Number of participants with adverse events (AEs), and serious adverse events (SAEs)Time frame: Approximately 45 months
  3. Number of participants with adverse events (AEs), and serious adverse events (SAEs) by SeverityTime frame: Approximately 45 months
  4. Number of participants with AEs leading to dose modificationsTime frame: Approximately 45 months

Locations

20 sites in 8 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    La Jolla, California · Recruiting

  • GSK Investigational Site

    Los Angeles, California · Recruiting

  • GSK Investigational Site

    Grand Rapids, Michigan · Recruiting

  • GSK Investigational Site

    Philadelphia, Pennsylvania · Recruiting

  • GSK Investigational Site

    West Valley City, Utah · Recruiting

  • GSK Investigational Site

    Melbourne, Victoria, Australia · Recruiting

  • GSK Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Montreal, Quebec, Canada · Recruiting

  • GSK Investigational Site

    Montpellier, France · Recruiting

  • GSK Investigational Site

    Villejuif, France · Recruiting

  • GSK Investigational Site

    Tokyo, Japan · Recruiting

  • GSK Investigational Site

    Tokyo, Japan · Recruiting

  • GSK Investigational Site

    Amsterdam, Netherlands · Recruiting

  • GSK Investigational Site

    Nijmegen, Netherlands · Recruiting

  • GSK Investigational Site

    Seoul, South Korea · Recruiting

  • GSK Investigational Site

    Seoul, Seoul Teugbyeolsi, South Korea · Recruiting

  • GSK Investigational Site

    Barcelona, Spain · Recruiting

  • GSK Investigational Site

    Málaga, Spain · Recruiting

  • GSK Investigational Site

    Logroño, La Rioja, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.